Related by context. All words. (Click for frequent words.) 75 Thrombolysis 74 Acute Myocardial Infarction 72 Oral Fingolimod 71 Unstable Angina 71 CLARITY TIMI 71 Pooled Analysis 71 Relapsing Multiple Sclerosis 71 Controlled Trial 70 Prospective Randomized 70 Acute Ischemic Stroke 70 Randomized Evaluation 70 registrational Phase 70 Randomized Study 70 Severe Sepsis 69 Patients Treated 69 Stent Restenosis 69 Subgroup Analysis 69 Percutaneous Coronary Intervention 69 Patients Treated With 68 unfractionated heparin UFH 68 Randomized Double blind 68 Carotid Revascularization Endarterectomy vs. 68 EURIDIS 68 Randomized Clinical Trial 68 Randomized Controlled Trial 68 Val HeFT 68 Patients Undergoing 68 Clinical Antipsychotic Trials 68 Randomized Double Blind 68 Coronary Artery Bypass Graft 68 Intervention Effectiveness 67 RE LY ® 67 stage IIIb IV 67 RECORD1 67 Randomized Phase 67 Platelet Inhibition 67 Completes Enrollment 67 Patients Receiving 67 II Clinical Trial 67 Prospective Randomized Trial 67 Stent Implantation 67 RAVEL 67 Randomized Trials 67 J Am Coll 67 Solid Tumors 67 XIENCE V demonstrated 67 Angiographic 67 Chronic Heart Failure 67 ST Segment Elevation 67 Acute Myocardial 67 Pivotal Clinical Trial 67 multicenter multinational 67 Phase III Clinical Trial 67 Combination REOLYSIN R 67 XIENCE V PROMUS Stent 67 ExTRACT TIMI 67 Phase 2b Clinical Trial 67 Elderly Patients 67 Meta Analysis 67 Study Evaluating 67 Castration Resistant Prostate Cancer 67 J Am Acad 67 Multicenter 67 Carotid Stenting 67 Randomized Controlled 66 Ischemic Stroke 66 Patient Outcomes 66 Complicated Skin 66 Heart Failure Patients 66 Acute Decompensated Heart Failure 66 Events MACE 66 Clinical Trial Results 66 Novel Oral 66 Is Well Tolerated 66 Pivotal Phase III 66 Trial Evaluating 66 Randomized Phase II 66 Eluting Stent 66 Meets Primary Endpoint 66 NSABP B 66 Improves Outcomes 66 Randomized Clinical Trials 66 Patency 66 Risk Stratification 66 TAXUS ATLAS 66 Pivotal Trial 66 Paclitaxel Eluting 66 Ischemic 66 Pegylated Liposomal Doxorubicin 66 Prospective Multicenter 66 Infarction 66 Atherosclerotic 66 Acute Coronary Syndromes 66 Diabetic Macular Edema 66 Enoxaparin 66 Initiated Phase 66 Major Adverse Cardiac 66 Randomized Double Blind Placebo 66 Left Ventricular 66 Hormone Refractory Prostate Cancer 66 Edge STudy 66 Phase III Trial 66 Demonstrates Positive 66 Cypher Sirolimus 65 Pivotal Phase 65 Venous Thromboembolism 65 Decompensated Heart Failure 65 Placebo Controlled Trial 65 landmark ATHENA 65 underwent resection 65 Randomized Controlled Trials 65 Unfractionated Heparin 65 undergoing elective percutaneous 65 Infarct 65 Randomised 65 CIMZIA TM certolizumab pegol 65 Placebo Controlled 65 placebo controlled Phase III 65 multicenter Phase III 65 Carotid Endarterectomy 65 Prolongs Survival 65 multicentre randomized double 65 Primary endpoints 65 Improves Survival 65 familial amyloidotic polyneuropathy FAP 65 failure ADHF 65 EVEREST II 65 Relapsed Multiple Myeloma 65 Renal Artery 65 Multicenter Randomized 65 q#h 65 Atypical Hemolytic Uremic Syndrome 65 aplastic anemia AA 65 Clinical Trial Evaluating 65 multicentre randomized 65 Pivotal Study 65 INCB# [003] 65 hypertrichosis occurred 65 Left Ventricular Dysfunction 65 Previously Treated 65 RECIST Response Evaluation Criteria 65 carotid artery stenting CAS 65 Heterozygous Familial Hypercholesterolemia 65 First Patient Enrolled 65 Dose Ranging Study 65 Hemodialysis Patients 65 Adjuvant Treatment 65 Clinical Outcome 65 Cholesterol Levels SPARCL 65 multicenter randomized controlled 65 Intracranial Aneurysms 65 Demonstrates Sustained 65 worsening thrombocytopenia 65 multicenter randomized placebo controlled 65 Vertebral Compression Fractures 65 Myocardial Ischemia 65 Refractory Angina 65 Relapsing Remitting Multiple Sclerosis 65 Lung Cancer Trial 65 Phase IIb Trial 65 patients undergoing percutaneous 65 receiving INTRON 65 Systemic Sclerosis 65 HCV RESPOND 2 65 Aggressive Reduction 65 Study Demonstrates 65 GOUT 65 Hsp# Inhibitor 65 relapsed MM 65 Bare Metal Stents 65 RE LY 65 Chronic Hepatitis C 64 prospective randomized controlled 64 evaluating tivozanib 64 Phase III AFFIRM 64 serum phosphorous 64 Controlled Study 64 PEGINTRON TM 64 Peripheral Arterial 64 STRIDE PD 64 J Clin 64 oxycodone CR 64 Adjuvant Chemotherapy 64 Adjunctive 64 Observational Study 64 Autologous Stem Cell Transplantation 64 Phase 2a Clinical Trial 64 #:#-# [031] 64 MIVI III 64 Randomized controlled 64 Cardiac Resynchronization Therapy 64 ischemic cardiomyopathy 64 Relapsed Refractory 64 Intracranial 64 Ranolazine 64 NAVISTAR R 64 Advanced Melanoma 64 By JENNIFER LEARN 64 somatostatin analog 64 randomized multicenter trial 64 multicenter placebo controlled 64 catheter occlusion 64 AA Amyloidosis 64 #-# Full Text 64 Percutaneous Tibial Nerve Stimulation 64 Achieves Primary Endpoint 64 induced macular edema 64 mg administered orally 64 myocardial infarction ventricular fibrillation 64 q8h 64 NEVO RES 64 Raloxifene Evaluation MORE 64 CCX# B 64 Aggressive Drug Evaluation 64 Antitumor Activity 64 Demonstrates Significant 64 Vascular Disrupting Agent 64 Metastatic Prostate Cancer 64 Aneurysm Repair 64 Ambulatory Blood Pressure 64 Orthop Surg 64 hemodynamically significant 64 Nilotinib 64 Antiviral Therapy 64 Orthostatic Hypotension 64 undergoing Percutaneous Coronary 64 Sustained Efficacy 64 TAXUS p value 64 Proc Am Soc 64 Clinical Outcomes Utilizing Revascularization 64 Multicenter Study 64 Carotid 64 colesevelam HCl 64 Occlusive Disease 64 Myocardial Infarction 64 alfa 2a 64 HCV SPRINT 64 oral rivaroxaban 64 5 FU leucovorin 64 mGluR5 negative 64 Postmenopausal Women 64 Eur J 64 Bivalirudin 64 Newly Diagnosed Multiple Myeloma 64 cisplatin gemcitabine 64 Phase IIb Clinical Trial 64 Doxil ® 64 unstable angina UA 64 tirofiban 64 CYPHER R Sirolimus eluting 64 Completes Patient Enrollment 64 prospective multicenter randomized 64 HALTS 64 MADIT 64 Metastatic Renal Cell Carcinoma 64 ug dose 64 bone marrow reticulin deposition 64 non valvular atrial 63 CHAMPION PCI 63 Index CDAI 63 Phase Ib Clinical Trial 63 Cutaneous T 63 Transcatheter 63 Long Term Efficacy 63 trials RCTs 63 Reduces Mortality 63 Stent Thrombosis 63 First Patient Dosed 63 Secondary Hyperparathyroidism 63 lopinavir r arm 63 Sirolimus Eluting 63 Brain Metastases 63 relapsed refractory multiple myeloma 63 Renal Cell Carcinoma 63 Phase 2b Study 63 comparing XIENCE V 63 Sorafenib HCC Assessment 63 Flu Cy 63 ribavirin RBV 63 IIIa inhibitor 63 binary restenosis 63 Prognostic Significance 63 Radiofrequency Ablation 63 MEND CABG 63 TRANSFORMS 63 neoadjuvant 63 Initiates Phase II 63 Cardiotoxicity 63 Intervention Trial 63 Nebulized 63 everolimus eluting stents 63 naïve HCV 63 R lenalidomide 63 sunitinib Sutent 63 Double Blind Placebo 63 Granted Orphan Drug 63 Non Alcoholic Steatohepatitis 63 Cardiol 63 Spectrum Pharmaceuticals Announces 63 occlusion PAO 63 complement inhibitor eculizumab 63 novel VDA molecule 63 descending thoracic 63 ACUITY trial 63 Refractory Hodgkin Lymphoma 63 Paroxysmal Nocturnal Hemoglobinuria PNH 63 SPIRIT FIRST 63 Diabetic Patients 63 Adjunctive Therapy 63 Free Full Text 63 valvular disease 63 See CLINICAL PHARMACOLOGY 63 mm Stent 63 Randomized Phase III 63 Initiates Clinical Trial 63 IN PATIENTS WITH 63 Placebo controlled 63 mcg QD 63 placebo controlled clinical 63 Group RTOG 63 Advanced Renal Cell 63 Cardiovascular Outcomes 63 Crit Care Med 63 CTAP# Capsules 63 TG MV 63 Single Dose 63 evaluating mipomersen 63 randomized multicenter 63 plus GP IIb 63 CYPHER ® Sirolimus eluting 63 bypass graft CABG surgery 63 Knee Osteoarthritis 63 Thromboembolism 63 epoetin alpha 63 mg BID dose 63 Tyrosine Kinase Inhibitor 63 Percutaneous Transluminal Coronary Angioplasty 63 Plus Ribavirin 63 Combination Treatment 63 Systemic Lupus Erythematosus SLE 63 Clinical Evaluation 63 Initiate Phase III 63 Follicular Lymphoma 63 bivalirudin monotherapy 63 AVOREN 63 Outpatient Setting 63 COPERNICUS 63 THAT ARE DIFFICULT TO 63 Vascular Grafts 63 evaluating REVLIMID 63 hyperphenylalaninemia HPA due 63 Phase III Pivotal Trial 63 Placebo Controlled Study 63 Well Tolerated 63 Mg Usa 63 Intervention Effectiveness CATIE 63 occlusion CRVO 63 Myocardial Infarction TIMI Study 63 undergoing coronary artery 63 paclitaxel eluting stents 63 candesartan cilexetil 63 Cell Lymphoma 63 unstable angina pectoris 63 MR Angiography 63 Sirolimus Eluting Stent 63 PLX STROKE targeting 63 everolimus eluting stent 63 Metastatic Colorectal Cancer 63 J Am Soc 63 J Shoulder Elbow 63 symptomatic BPH 63 AIR CF1 63 undergone radical prostatectomy 63 #.#mg/dL 63 Catheter Ablation 63 Cardiac Resynchronization 63 multicenter randomized double 63 Overactive Bladder 63 workhorse lesions 63 Rheumatoid Arthritis Patients 63 Tumor Response 62 MADIT II 62 Localized Prostate Cancer 62 Telaprevir VX 62 Metastatic Melanoma 62 Paroxysmal Atrial Fibrillation 62 number NCT# ClinicalTrials.gov 62 atypical Hemolytic Uremic Syndrome 62 Pharmacokinetics PK 62 Central Retinal Vein 62 TO AVOID PREGNANCY WHILE 62 Fractional Flow Reserve 62 Microplasmin 62 stent DES 62 acute peripheral arterial 62 ALN HPN 62 #mg QD [002] 62 retinal vein occlusion induced 62 J Natl Cancer Inst 62 Bosutinib 62 Renal Impairment 62 Renal Function 62 Score TOS 62 multicenter prospective 62 PEG IFN 62 Demonstrate Significant 62 ACCOMPLISH 62 Surgical Treatment 62 Restenosis 62 multicenter randomized 62 See WARNINGS 62 Intravitreal 62 Bare Metal Stent 62 Previously Untreated 62 Phase 2a Study 62 TMC# C# 62 Intracerebral Hemorrhage 62 Coronary Intervention 62 Dose Escalation 62 Diffuse Large B 62 Primary Hypercholesterolemia 62 Treatment Outcome 62 Gastric Cancer 62 STENT 62 Rating Scale MADRS 62 landmark ATHENA trial 62 ischemia driven 62 Clin Oncol 62 lexidronam injection 62 Receives Orphan Drug Designation 62 PERSEUS 62 ACTEMRA TM 62 thromboembolic complications 62 CYP#A# CYP#D# 62 Crit Rev 62 blinded randomized placebo controlled 62 Antigen Specific 62 carotid endarterectomy CEA 62 phase IIb clinical 62 underwent CABG 62 Accelerated Partial Breast Irradiation 62 morphometric vertebral fractures 62 bronchial hyperresponsiveness 62 ritonavir boosted 62 Phase 2b Trial 62 FOLFOX6 chemotherapy regimen 62 Glucosamine Chondroitin Arthritis 62 dalteparin 62 aneurysms AAA 62 ENDEAVOR IV 62 Antiplatelet Therapy 62 Cardiovascular Events 62 Initiates Enrollment 62 Severe Asthma 62 Naive Patients 62 treatment naïve genotype 62 Tiotropium 62 Renal Insufficiency 62 plus glycoprotein IIb 62 Soft Tissue Sarcoma 62 Ventricular Tachycardia 62 assessing T DM1 62 Am J Respir 62 deep venous thromboses 62 recurrent glioblastoma multiforme 62 recurrent malignant glioma 62 Stereotactic Body Radiation Therapy 62 BR.# 62 SORT OUT III 62 myocardial infarction hypersensitivity 62 Sirolimus eluting Coronary Stent 62 abacavir lamivudine 62 radiofrequency RF ablation 62 Commences Phase 62 interferon gamma 1b 62 Significantly Reduces 62 Endeavor Drug Eluting 62 Stenting 62 multicentre randomized controlled 62 CYT# potent vascular disrupting 62 EQUATE OB 62 achieved CCyR 62 SPRYCEL ® 62 mg TID 62 Arch Neurol 62 Arch Intern Med 62 metastatic GIST 62 restenotic lesions 62 Long Lesion 62 CALGB # [002] 62 Radical Prostatectomy 62 Left Ventricular Hypertrophy 62 Arimidex Tamoxifen Alone 62 acute coronary syndromes ACS 62 pan HDAC inhibitor 62 stable angina pectoris 62 J Allergy Clin 62 Curr Opin 62 receiving prophylactic anticoagulation 62 interferon beta 1a infertility 62 Nephrol Dial Transplant 62 BOLDER II 62 ASH Abstract # 62 Ann Oncol 62 Fondaparinux 62 8mg/kg 62 Hospital Acquired Pneumonia 62 Shows Efficacy 62 Folfox 62 stage IIIB 62 NCCTG N# 62 Neovascular Age Related Macular 62 Renal Cell Carcinoma RCC 62 Endovascular Valve Edge 62 Pediatric Patients 62 REYATAZ r arm 62 Investigational Treatment 62 INSPIRE Trial Phase III 62 headache nasopharyngitis 62 Files IND 62 Phase IIIb 62 Monitoring ABPM 62 Solid Tumors criteria 62 DEFER 62 infliximab monotherapy 62 Hepatocellular Carcinoma 62 Preclinical Data 62 primary hypercholesterolemia 62 coronary intervention 62 Novel Inhibitor 62 Int J Radiat Oncol 62 EINSTEIN DVT 62 Treated Patients 62 Breast Carcinoma 61 Hypertensive Patients 61 allogeneic hematopoietic stem cell 61 drug eluting stent implantation 61 Myelodysplastic Syndrome MDS 61 prospective multicenter 61 phase IIIb 61 ECASS 61 ARCOXIA 61 Endarterectomy 61 deCODE AF TM 61 Syncria R 61 Peginterferon 61 Peginterferon Alfa 2a 61 ADONIS 61 orally inhaled migraine 61 Initiate Phase 61 calculated creatinine clearance 61 aspirin clopidogrel 61 plus prednisone 61 Investigational Drug 61 postoperative AF 61 nadolol 61 Multicenter Phase 61 Embolic 61 Venous Thrombosis 61 Acute Coronary Syndromes ACS 61 Hernia Repair 61 undergoing percutaneous coronary 61 ENL recurrence 61 Post Operative 61 Advanced Prostate Cancer 61 Combination Therapy 61 non splenectomized 61 mcg BID 61 Eur J Endocrinol 61 Chronic Myeloid Leukemia 61 Chronic Lymphocytic Leukemia 61 Tumor Progression 61 peripheral arterial occlusive disease 61 ST Elevation Myocardial 61 Sirolimus eluting 61 severe neutropenia 61 Induction Therapy 61 prospective nonrandomized 61 STEALTH C 61 induce orthostatic hypotension 61 Patients Enrolled 61 refractory chronic lymphocytic 61 label multicenter 61 Systematic Review 61 IMPACT DCM 61 #mg BID [003] 61 mg QD 61 cyclophosphamide methotrexate 61 Stenting Trial CREST 61 Safety Tolerability 61 NYHA Class II 61 Vidaza ® 61 infarction NSTEMI 61 Plaque Psoriasis 61 Cilostazol 61 J Clin Oncol 61 #mg dosing group 61 Hormone Receptor Positive 61 metastatic castration resistant 61 Randomised Trial 61 Non Alcoholic Fatty 61 Acute Coronary Syndrome 61 myelodysplastic myeloproliferative diseases 61 Lung Injury 61 nab paclitaxel 61 tolvaptan 61 Montgomery Asberg Depression 61 INTEGRILIN R 61 HCV Protease Inhibitor 61 RENAL 61 Juvenile Idiopathic Arthritis 61 CAPRIE 61 vitreoretinal disorders 61 Fixed Dose 61 Demonstrated Significant 61 thromboembolic 61 dose escalation clinical 61 brand ciclesonide HFA 61 Anticancer Drugs 61 HER2 Positive Breast Cancer 61 PREZISTA r arm 61 Bone Metastases 61 Clinical Efficacy 61 unresectable HCC 61 myocardial infarction stroke 61 Chronic Bronchitis 61 Physical Function 61 randomized controlled multicenter 61 Irbesartan 61 Brentuximab Vedotin SGN 61 Eprodisate 61 plus COPEGUS 61 PCI ExTRACT TIMI 61 Ejection Fraction 61 Mycophenolate Mofetil 61 double blinded randomized 61 Metabolic Efficiency 61 fluvastatin 61 Monotherapy 61 Hypotension 61 AVONEX ® 61 eluting stent 61 bortezomib refractory 61 PEGylated interferon beta 1a 61 Colorectal Cancer Patients 61 R Saizen R 61 Patients Suffering 61 Hepatitis C Genotype 61 zonisamide SR 61 REYATAZ r 61 PROMUS Element Stent 61 fosbretabulin 61 Predict Risk 61 Invasive Breast Cancer 61 Adjuvant Therapy 61 Neoadjuvant 61 Patient Enrollment 61 noninferior 61 patients undergoing CABG 61 treatment naive genotype 61 Orally Active 61 EnteroMedics proprietary neuroblocking technology 61 Parathyroid Hormone 61 Abciximab 61 haematologic 61 ANN INTERN MED 61 imipramine Tofranil 61 Confirmatory Phase 61 Improve Survival 61 FEMALES SHOULD BE ADVISED 61 Myelodysplastic Syndromes 61 CABG Surgery 61 Treatment Experienced 61 CALERIE 61 Chronic Renal Failure 61 Shows Promising 61 angioplasty stenting 61 Scale EDSS 61 erythematosus SLE 61 FDA APPROVES 61 papillary renal cell carcinoma 61 VELCADE melphalan 61 orally administered inhibitor 61 Eluting Coronary Stent System 61 Albuferon TM 61 Investigational Agent 61 erythematosus 61 REALITY Trial 61 LENALIDOMIDE 61 hydroxymethyl coenzyme 61 Polyp Prevention Trial 61 Immunomedics Announces 61 recombinant tissue plasminogen 61 J Pediatr 61 Heart Failure Trial 61 liposome injection 61 Multicenter Randomized Double 61 REMINDER ORLive Presents 61 comparator arm 61 nondiabetic patients 61 #:#-# [025] 61 DAPT 61 Investigational Compound 61 Exacerbation 61 CYPHER Stent 61 daily Infergen 61 Uterine Fibroid Embolization 61 Presents Positive 61 ISTODAX ® 61 demonstrated clinically meaningful 61 Antiplatelet 61 Tolerability 61 Statistically Significant 61 Child Adolesc Psychiatry 61 biliary tract cancer 61 Enrolls First 61 Treating Chronic 61 Phase #b/#a clinical 61 NMIBC 61 Drug Eluting 61 Aflibercept 61 LUX Lung 61 EchoCRT 61 Preclinical Study 61 known dihydropyrimidine dehydrogenase 61 CLARITY study 61 Significantly Improves 61 ROCKET AF 61 Prevent Stroke 61 Intravascular 61 Lymphocytic 61 Treatment Naïve 61 Ann Rheum Dis 61 PROWESS 61 Systolic Hypertension 61 Liver Failure 61 Long Term Outcomes 61 SPIRIT IV 61 concomitant cardiac 61 HER2 Positive 61 FASEB J. 61 melphalan prednisone 61 Statin Therapy 61 Nephrol 61 primary percutaneous coronary 61 Prophylactic Treatment 61 essential thrombocythemia ET 61 neutropenia dehydration dyspnea 60 dependent kinase inhibitor 60 RE MODEL 60 Phase IIa Clinical Trial 60 postmenopausal osteoporotic women 60 Cancer Incidence Mortality 60 vapreotide acetate 60 vinca alkaloid 60 Carcinomas 60 mg qd 60 antiplatelet agent 60 advanced metastatic renal 60 IV NSCLC 60 blind multicenter 60 Complete Remission 60 metastatic malignant 60 nicardipine 60 prospectively stratified 60 dasatinib Sprycel ® 60 TMC# r 60 Chronic Hepatitis B 60 substudy 60 MEK Inhibitor 60 Successfully Completes Phase 60 Antiviral Activity 60 ASTEROID 60 humanized interleukin 6 60 Critical Limb Ischemia CLI 60 Taxus Stent 60 Elagolix 60 multicenter randomized clinical 60 REVIVE Diabetes 60 heFH 60 J Antimicrob Chemother 60 Glycemic Control 60 Dual Antiplatelet Therapy 60 CYPHER R Sirolimus Eluting 60 periprocedural 60 TAXUS Express2 60 Nesiritide 60 Myelofibrosis 60 Resistant Hypertension 60 surgically resected 60 Drug Candidate 60 5 Fluorouracil 60 Total Knee Replacement 60 Survival Benefit 60 systemic anaplastic large 60 Proves Effective 60 TAXUS Express Stent 60 Clostridium difficile Infection 60 certolizumab 60 ipsilateral stroke 60 NATRECOR R 60 Non Responders 60 XIENCE V Everolimus Eluting 60 LEVAQUIN ® 60 transplantation HCT 60 lintuzumab SGN 60 metastatic ocular 60 zotarolimus eluting stent 60 TAXUS V 60 adjunctive placebo 60 Total Knee Arthroplasty 60 Eur Respir J 60 Subtypes 60 Fungal Infections 60 MKC# MT 60 Sipuleucel T 60 Xelox 60 Multiple Myeloma MM 60 unresectable liver cancer 60 Renal Cancer 60 castrate resistant prostate cancer 60 NCT# ClinicalTrials.gov 60 prospective multicenter study 60 irinotecan containing 60 HORIZONS AMI 60 Coronary Artery Calcium 60 5q MDS 60 Nonalcoholic Fatty Liver Disease 60 Hodgkin lymphoma HL 60 Vertebroplasty 60 Relapsed Refractory Multiple Myeloma 60 Lenalidomide 60 Robotic Assisted 60 GP IIb IIIa inhibitors 60 sirolimus stent 60 Novel Compound 60 Primary Endpoint 60 Topline Results 60 intravesical infusion therapy 60 Node Positive 60 Initiates Phase III 60 DIRECT Trial 60 Presents Preclinical Data 60 invasive candidiasis 60 Response Evaluation Criteria 60 Acute Exacerbations 60 de novo kidney transplant 60 TNF Tumor Necrosis Factor 60 Successfully Treats 60 Lowers Risk 60 Phase 2a Trial 60 Teva Provides Update 60 5 fluorouracil leucovorin 60 Pegasys ® 60 Shows Statistically Significant 60 Treating Heart Failure 60 Hypercholesterolemia 60 heparin induced thrombocytopenia 60 R# #mg BID 60 THERAPY FOR 60 Non inferiority 60 Tocilizumab 60 ATACAND 60 BENICAR 60 Relapsed 60 Neoadjuvant Chemotherapy 60 HBeAg negative patients 60 receiving VELCADE 60 plus methotrexate 60 Perifosine KRX 60 Chemotherapeutic Agents 60 Therapy Improves 60 Dermatol 60 Overactive Bladder OAB 60 Mg Uk 60 subanalysis 60 receiving golimumab 60 Motexafin Gadolinium 60 SYNTAX 60 mcg kg REBETOL 60 underwent surgical resection 60 Breast Cancer Recurrence 60 ipsilateral breast 60 mg RDEA# 60 Adjuvant Breast Cancer 60 PEGylated Fab fragment 60 Generalized Anxiety Disorder 60 Preclinical Models 60 Pemetrexed 60 randomized Phase III 60 FDA Approvals 60 Adenoma 60 Multicentre 60 Antihypertensive 60 cell lymphoma CTCL 60 pT2 60 TAXUS IV 60 Chemoradiation 60 symptomatic paroxysmal AFib 60 purpura ITP 60 CHARM Added 60 THE ORLANDO FLA. 60 Versus Placebo 60 metastatic colorectal carcinoma 60 leukemia AML 60 Neovascular AMD 60 metastatic neuroendocrine tumors 60 4mg/kg 60 invasive aspergillosis 60 Hepatocellular 60 CARDIOVASCULAR 60 mcg linaclotide 60 J Child Adolesc 60 RADIANT 60 fibrillation AF 60 events thrombocytopenia neutropenia 60 Inhaled Corticosteroids 60 PREVAIL 60 Diabetic Nephropathy 60 Lipid Lowering Treatment 60 prospectively randomized 60 Diabetic Macular Edema DME 60 Androgen Deprivation Therapy 60 PEGylated anti 60 mg q#h 60 noninferiority 60 MGd 60 kidney urologic 60 arsenic trioxide injection 60 Multiple Ascending Dose 60 Interferon Beta 60 macular edema secondary 60 Appears Safe 60 atherothrombotic disease 60 Aortic Stenosis 60 Tolvaptan 60 adult chronic ITP 60 N Engl J 60 prospective multicentre 60 Natalizumab 60 prospective randomized multicenter 60 Vaccine Adjuvant 60 CCyR 60 Cardiac Allograft Rejection 60 achieved ACR# 60 lumbar spine BMD 60 Liver Metastases 60 coronary revascularization 60 Arterial Disease 60 Cerebril TM 60 Nat Clin Pract 60 Double Blind Randomized 60 Progenitor Cells 60 Antitumor activity 60 Clinical Outcomes 60 Radiation Therapy Oncology 60 TAXUS Liberte Long 60 FOLFOX6 60 prospective observational 60 sirolimus eluting 60 FUSILEV enhances 60 Arch Facial Plast 60 ORLive Presents 60 unresectable tumors 60 CATIE AD 60 transluminal coronary angioplasty PTCA 60 Study Showed 60 Vildagliptin 60 TRANSDUR ® 60 Gliadel R 60 Diabetic Foot Ulcer 60 Abstract Accepted 60 endoscopic remission 60 moderate hepatic impairment 60 ERBITUX cetuximab 60 THE LARGEST CANADIAN 60 Improved Survival 60 beta 1a 60 nonrandomized 60 plus dexamethasone 60 Pharmacokinetic Study 60 BRIM2 60 Symptom Relief 60 Non Inferiority 60 allosteric modulator NAM 60 VICTOR E3 60 Atrial 60 Tezampanel 60 Malignant Melanoma 60 BARACLUDE ® 60 NEVO 60 ventricular tachyarrhythmia 60 HES CEL 60 Efficacy Trial 60 ENDEAVOR II 60 histologically confirmed 60 Coronary Angiography 60 dual endothelin receptor antagonist 60 alfuzosin